



(12) Translation of  
European patent specification

(11) NO/EP 3321279 B1

NORWAY

(19) NO  
(51) Int Cl.  
**C07K 14/605 (2006.01)**  
**A61K 38/26 (2006.01)**  
**A61P 3/10 (2006.01)**

**Norwegian Industrial Property Office**

---

(45) Translation Published 2020.04.27

(80) Date of The European Patent Office Publication of the Granted Patent 2020.02.12

(86) European Application Nr. 16848039.0

(86) European Filing Date 2016.09.13

(87) The European Application's Publication Date 2018.05.16

(30) Priority 2015.09.25, CN, 201510619012

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

(73) Proprietor BrightGene Bio-Medical Technology Co., Ltd., Building C25, No. 218 Xinghu Street, BioBay Suzhou Industrial Park SuzhouJiangsu 215123, Kina

(72) Inventor YUAN, Jiandong, Building C25 No. 218 Xinghu Street BioBay Suzhou Industrial Park, Suzhou Jiangsu 215123, Kina  
HUANG, Yangqing, Building C25 No. 218 Xinghu Street BioBay Suzhou Industrial Park, Suzhou Jiangsu 215123, Kina  
SONG, Yunsong, Building C25 No. 218 Xinghu Street BioBay Suzhou Industrial Park, Suzhou Jiangsu 215123, Kina  
YUAN, Fang, Building C25 No. 218 Xinghu Street BioBay Suzhou Industrial Park, Suzhou Jiangsu 215123, Kina

(74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

---

(54) Title **EXENATIDE MODIFIER AND USE THEREOF**

(56) References Cited: CN-A- 103 237 561, US-A1- 2010 184 641, CN-A- 101 980 725, WO-A1-2006/097538  
CHAE S Y ET AL: "The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 144, no. 1, 21 May 2010 (2010-05-21), pages 10-16, XP027036550, ISSN: 0168-3659 [retrieved on 2010-04-30]  
ZHOU J ET AL: "Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 72, no. 2, 1 June 2009 (2009-06-01), pages 412-417, XP026119126, ISSN: 0939-6411, DOI: 10.1016/J.EJPB.2009.02.001 [retrieved on 2009-02-07]

SHECHTER YORAM ET AL: "Newly designed modifier prolongs the action of short-lived peptides and proteins by allowing their binding to serum albumin.", BIOCONJUGATE CHEMISTRY 15 AUG 2012, vol. 23, no. 8, 15 August 2012 (2012-08-15), pages 1577-1586, XP002779559, ISSN: 1520-4812

JUHO LEE ET AL: "Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 424, no. 1-2, 1 March 2012 (2012-03-01), pages 50-57, XP055069410, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2011.12.050


KONG J H ET AL: "Long acting hyaluronate @? exendin 4 conjugate for the treatment of type 2 diabetes", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 31, no. 14, 1 May 2010 (2010-05-01), pages 4121-4128, XP026947588, ISSN: 0142-9612, DOI: 10.1016/J.BIOMATERIALS.2010.01.091 [retrieved on 2010-02-10]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


**Patentkrav**

1. Exenatidmodifiserer eller farmasøytisk akseptable salter derav som har GLP-1-reseptoragonistaktivitet, som vist i formel (I):

5 (Ex-4)-L-Y (I)










hvor Ex-4 er exendin-4; L er  $\text{---}$  for å koble Ex-4 med Y; L' er en hydrofil kjede som inneholder en etergruppe; Y er en alifatisk kjede med en terminal karboksylgruppe, hvori exenatidmodifisereren er:










10 k er et hvilket som helst heltall mellom 6-20.

2. Exenatidmodifisereren eller farmasøytisk akseptable salter derav ifølge krav 1, hvori L velges fra:







- 2 -




hvori m er et hvilket som helst heltall mellom 2-20; n er et hvilket som helst heltall mellom 2-20; r er et hvilket som helst heltall mellom 1-6.

5

3. Exenatidmodifisereren eller farmasøytisk akseptable salter derav ifølge krav 1, hvori exenatidmodifisereren er:



- 3 -




hvori m er et hvilket som helst heltall mellom 2-20; n er et hvilket som helst heltall mellom 2-20; r er et hvilket som helst heltall mellom 1-6; k er et hvilket som helst heltall mellom 6-20.

5

4. Exenatidmodifisereren eller farmasøytisk akseptable salter derav ifølge krav 3, omfattende de følgende forbindelsene:



- 5 -



5. Exenatidmodifisereren eller farmasøytisk akseptable salter derav ifølge krav 1 eller 2 for anvendelse i behandling av sykdommer og/eller symptomer assosiert med glykometabolisme,

- 6 -

eller for anvendelse i behandlingen av diabetes,  
eller for anvendelse i behandlingen av fettlever,  
eller for anvendelse i fremgangsmåten for vekttap.

5 6. Farmasøytisk sammensetning omfattende exenatidmodifisereren eller  
farmasøytisk akseptable salter derav ifølge krav 1 eller 2 og eventuelt farmasøytisk  
akseptable bærere.

7. Sammensetningen ifølge krav 6 for anvendelse i behandlingen av sykdommer  
10 og/eller symptomer assosiert med glykometabolisme,  
eller for anvendelse i behandlingen av diabetes,  
eller for anvendelse i behandlingen av fettlever,  
eller for anvendelse i fremgangsmåten for vekttap.